About tRNA-queuosine alpha-mannosyltransferase
tRNA-queuosine alpha-mannosyltransferase (QTMAN) is a protein
from Homo sapiens identified by UniProt accession
Q4AE62, 458 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | tRNA-queuosine alpha-mannosyltransferase |
| UniProt accession | Q4AE62 |
| Gene | QTMAN |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (69)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.42
- cognitive function measurement · score 0.37
- Oral ulcer · score 0.30
- ulcer disease · score 0.29
- mean corpuscular hemoglobin concentration · score 0.16
- mean corpuscular volume · score 0.15
- mean corpuscular hemoglobin · score 0.15
- schizophrenia · score 0.14
- erythrocyte count · score 0.14
- body weight · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q4AE62-F1 | alphafold | PREDICTED | 82.35 | — |
Amino-acid sequence (458 residues)
MSILIIEAFY GGSHKQLVDL LQEELGDCVV YTLPAKKWHW RARTSALYFS QTIPISEHYR TLFASSVLNL TELAALRPDL GKLKKILYFH ENQLIYPVKK CQERDFQYGY NQILSCLVAD VVVFNSVFNM ESFLTSMGKF MKLIPDHRPK DLESIIRPKC QVIYFPIRFP DVSRFMPKHK TTHLKKMLGL KGNGGAVLSM ALPFQPEQRD SEDLLKNFNS ECDTHCGLDT ARQEYLGNSL RQESDLKKST SSDNSSSHHG ENKQNLTVDP CDILGGVDNQ QRLLHIVWPH RWEHDKDPES FFKVLMHLKD LGLNFHVSVL GETFTDVPDI FSEAKKALGS SVLHWGYLPS KDDYFQVLCM ADVVISTAKH EFFGVAMLEA VYCGCYPLCP KDLVYPEIFP AEYLYSTPEQ LSKRLQNFCK RPDIIRKHLY KGEIAPFSWA ALHGKFRSLL TTEPREDL
Explore tRNA-queuosine alpha-mannosyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets